View more prostate cancer trials »

3-Dimensional Transrectal Ultrasound for Prostate Cancer Diagnosis and Surveillance
Aims: To evaluate the impact of using a 3-dimensional transrectal ultrasound for diagnosis and surveillance of prostate cancer. Before the Food and Drug Administration (FDA) approved 3-D ultrasounds, all prostate biopsies were performed using 2-dimensional images. The 3-D technology potentially allows for better visualization to increase accuracy of needle placement when sampling different parts of the prostate. The study involves access to your medical record and does not include any additional procedures.
Diagnosis: Undergoing 3-D Prostate Biopsy
Principal Investigator: Michael McGuire, MD
IRB Approval Number: EH10-379
Sponsor: NorthShore University HealthSystem
Contact: Study Coordinator, Jackie Petkewicz at 847.503.4282
Open to Enrollment: Yes

Prostate Cancer Susceptibility: The ICPCG Study (International Consortium for Prostate Cancer Genetics)
Aims: To determine the genetic basis of prostate cancer. Families with at least two men affected with prostate cancer are likely to harbor genetic susceptibility to the disease. By studying these families, researchers may identify new genes or genetic mutations that may predispose certain men to prostate cancer or aggressive disease. The study involves a one-time blood draw and a minimal one-time questionnaire.
Diagnosis: A Family History of Prostate Cancer
Principal Investigator: Brian Helfand, MD, PhD
IRB Approval Number: EH13-250
Sponsor:  John and Carol Walter Center for Urological Health
Contact: Study Coordinator, Jasmine Nero at 847.503.3087
Open to Enrollment:

The Impact of Using Genetic Risk Scores (GRSs) for Inherited Risk Assessment of Prostate Cancer
Aims: To assess the usefulness of an investigational genetic test called GRS that, in this study, will generate a score that describes a man's risk of developing prostate cancer.  Before GRS can be offered outside of a research setting, it is important to assess patients' understanding, opinions and responses to the test.  This will be done via questionnaires.
Diagnosis: Men at Risk for Prostate Cancer 
Principal Investigator: Jianfeng Xu, MD, PhD
IRB Approval Number: EH16-239
Sponsor: NorthShore University HealthSystem
Contact: Study Coordinators, Elena Genova-Peeva at 224.364.7413 or Jasmine Nero at 847.503.3087 
Open to Enrollment: Yes

Phenotyping Study Protocol
Aims: To provide valuable information to researchers about patients' experiences with urinary symptoms and how the symptoms are managed by the urologist. We want to understand the important differences among people and what factors affect urinary and bladder problems. The ultimate goal of this study is to collect information that will improve the care and treatment for people with urinary and bladder problems.
Diagnosis: Lower Urinary Tract Symptoms 
Principal Investigator: Brian Helfand, MD, PhD
IRB Approval Number: EH15-143
Sponsor: National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Contact: Study Coordinator, Pooja Talaty at 847.503.4280
Open to Enrollment: Yes

Compliance and Outcomes with Penile Rehabilitation in Men after Prostate Cancer Treatment
Aims: To determine the impact of sexual function rehabilitation on quality of life in men who have undergone prostate cancer treatment with either surgery or radiation therapy. Treatment compliance and satisfaction will be measured. The study involves periodic questionnaires.
Diagnosis: Sexual Dysfunction following Prostate Cancer Treatment 
Principal Investigator: Jeffrey Albaugh, PhD, APRN
IRB Approval Number: EH13-049
Sponsor: NorthShore University HealthSystem
Contact: Nurse Navigator, Martha McCurdy at 847.503.4245 or Study Coordinator, Rafael Escobar at 847.503.4281
Open to Enrollment: Yes

Clinical Validation of a Urine-Based Assay with Genomic and Epigenomic Markers for Predicting Recurrence during Non-Muscle Invasive Bladder Cancer Surveillance
Aims: To determine the ability of a experimental urine test to detect recurrence in patients with previously-diagnosed bladder cancer.  The sponsor hopes that this new test will reduce the need for cystoscopy in patients who are unlikely to have a recurrence and improve compliance in patients who need to have a cystoscopy.
Diagnosis: Non-Invasive Bladder Cancer
Principal Investigator: Brian Helfand, MD, PhD
IRB Approval Number: EH16-009
Sponsor: NorthShore University HealthSystem
Contact: Study Coordinator, Jasmine Nero at 847.503.3087 
Open to Enrollment: Yes

REASSURE ME: Reducing the Effects of Active Surveillance Stress, Uncertainty and Rumination thru Engagement in Mindfulness Education
Aims: To examine an 8-week health promotion and lifestyle wellness program intended to improve the quality of life in men (and their partners, if applicable) diagnosed with prostate cancer who are being followed by active surveillance.  The study will allow health care professionals to learn more about how these different health and wellness interventions work and if they should become a part of regular supportive care services for patients.
Diagnosis: Prostate Cancer Being Followed by Active Surveillance 
Principal Investigator: Charles Brendler, APRN
IRB Approval Number: EH15-124
Sponsor: NorthShore University HealthSystem
Contact: Study Coordinator, Rafael Escobar at 847.503.4281
Open to Enrollment: Yes

MOSAIC-P: Mindfulness Online for Symptom Alleviation and Improvement in Cancer of the Prostate
Aims: To test a 4-week mindfulness program that is intended to reduce stress and improve the quality of life of patients with metastatic prostate cancer.  This program has the potential to help cancer patients learn effective ways to decrease stress and improve quality of life.
Diagnosis: Metastatic Prostate Cancer
Principal Investigator: Britt Hanson, DO
IRB Approval Number: EH15-403
Sponsor: NorthShore University HealthSystem
Contact: Study Coordinator, Rafael Escobar at 847.503.4281 
Open to Enrollment: Yes